Tuesday, March 02, 2010 4:07:47 PM
MMs holding this down in my opinion.
I was watching Level II almost all day on this one. I can not believe how it traded in a very very narrow band today. Even up through closing when the MMs large volumne of 100, 200 shares were being traded, they would add on more and more just to keep the price down - at least how I was seeing this being traded today. I think we should have been easily over 2.00 and could see it maybe a new high, but was held down once the market was open. Before than, this was pushing 2.07 or more in pre-open hours and looked like it was heading higher.
I was watching Level II almost all day on this one. I can not believe how it traded in a very very narrow band today. Even up through closing when the MMs large volumne of 100, 200 shares were being traded, they would add on more and more just to keep the price down - at least how I was seeing this being traded today. I think we should have been easily over 2.00 and could see it maybe a new high, but was held down once the market was open. Before than, this was pushing 2.07 or more in pre-open hours and looked like it was heading higher.
Recent HRTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:06:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 12:30:11 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/27/2026 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:00:26 PM
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results • GlobeNewswire Inc. • 02/26/2026 01:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 07:40:59 PM
- Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:30:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 08:00:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 07:49:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 07:39:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2026 06:08:24 PM
- Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth • GlobeNewswire Inc. • 01/09/2026 02:29:00 PM
- Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) • GlobeNewswire Inc. • 12/04/2025 01:15:00 PM
